TAGCyx Biotechnologies None
TAGCyx Biotechnologies has developed a technology platform called Xenoligo, which enables the discovery of high functional oligonucleotide drugs. This platform uses genetic alphabet expansion to create customized nucleic acids for therapeutic applications. The company can produce DNA aptamers through this platform, which is an innovative artificial base pairing technology. Aptamers are single-stranded oligonucleotide molecules that represent the next generation of drug modality. TAGCyx Biotechnologies aims to produce more effective and safer medicines and medical devices at a low cost and contribute to society by delivering therapies to as many people as possible.
Headquarters:
Tokyo, Tokyo, Japan
Employee Number:
11-50
Estimated Revenue:
$5 million